胡芷柔;徐海燕;徐冬冬;李辉;

• 1:中国医学科学院北京协和医学院北京协和医院眼科

摘要(Abstract)：

<正>甲状腺相关眼病(thyroid associated ophthalmopathy,TAO)是一种常见的眼眶疾病,发病率居成人眼眶病首位。TAO与自身免疫性甲状腺疾病有关,主要发生在格雷夫斯病(Graves'disease,GD)甲状腺功能亢进患者中,少数发生在甲状腺功能低下或正常患者中,发病率女性16/10万,男性2.9/10万[1]。眼部表现与甲状腺功能异常可同时、提前或

关键词(KeyWords)： 甲状腺相关眼病;免疫治疗;利妥昔单抗;托珠单抗

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81271043)

作者(Author): 胡芷柔;徐海燕;徐冬冬;李辉;

Email:

DOI:

参考文献(References)：

• [1]Bartley GB.The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County,Minnesota[J].Trans Am Ophthalmol Soc,1994,92:477-588.
• [2]Wiersinga WM,Smit T,van der Gaag R,et al.Temporal relationship between onset of Graves'ophthalmopathy and onset of thyroidal Graves'disease[J].J Endocrinol Invest,1988,11:615-619.
• [3]Bahn RS.Graves'ophthalmopathy[J].N Engl J Med,2010,362:726-738.
• [4]Mourits MP,Prummel MF,Wiersinga WM,et al.Clinical activity score as a guide in the management of patients with Graves'ophthalmopathy[J].Clin Endocrinol,1997,47:9-14.
• [5]Bartalena L,Baldeschi L,Dickinson A,et al.Consensus statement of the European Group on Graves'orbitopathy(EUGOGO)on management of GO[J].Eur J Endocrinol,2008,158:273-285.
• [6]Smith TJ.Pathogenesis of Graves'orbitopathy:a 2010 update[J].J Endocrinol Invest,2010,33:414-421.
• [7]Zang S,Ponto KA,Kahaly GJ.Clinical review:intravenous glucocorticoids for Graves'orbitopathy:efficacy and morbidity[J].J Clin Endocrinol Metab,2011,96:320-332.
• [8]Shams PN,Ma R,Pickles T,et al.Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease[J].Am J Ophthalmol,2014,157:1299-1305.
• [9]Kazim M,Garrity JA.Orbital radiation therapy for thyroid eye disease[J].J Neuroophthalmol,2012,32:172-176.
• [10]Pillar AJ,Richa DC.Treatment options for thyroid eye disease[J].Curr Treat Options Neurol,2014,16:303.
• [11]Salvi M,Vannucchi G,Beck-Peccoz P.Potential utility of rituximab for graves'orbitopathy[J].J Clin Endocrinol Metab,2013,98:4291-4299.
• [12]Salvi M,Vannucchi G,Campi I,et al.Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression[J].Eur J Endocrinol,2006,154:511-517.
• [13]Mitchell AL,Gan EH,Morris M,et al.The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves'orbitopathy[J].Clin Endocrinol,2013,79:437-442.
• [14]Salvi M,Vannucchi G,Curro N,et al.Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves'orbitopathy:A randomized controlled study[J].J Clin Endocrinol Metab,2015,100:422-431.
• [15]Savino G,Balia L,Colucci D,et al.Intraorbital injection of rituximab:A new approach for active thyroid-associated orbitopathy,a prospective case series[J].Minerva Endocrinol,2013,38:173-179.
• [16]Herold KC,Gitelman SE,Ehlers MR,et al.Teplizumab(anti-CD3 m Ab)treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial:metabolic and immunologic features at baseline identify a subgroup of responders[J].Diabetes,2013,62:3766-3774.
• [17]Rossi D,Modena V,Sciascia S,et al.Pheumatoid arthritis:Biological therapy other than anti-TNF[J].Int Immunopharmacol,2015,27:185-188.
• [18]Perez-Moreiras JV,Alvarez-Lopez A,Gomez EC.Treatment of active corticosteroid-resistant Graves'orbitopathy[J].Ophthal Plast Reconstr Surg,2014,30:162-167.
• [19]Dinarello CA,Simon A,van der Meer JW.Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases[J].Nat Rev Drug Discov,2012,11:633-652.
• [20]Tan GH,Dutton CM,Bahn RS.Interleukin-1(IL-1)receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves'ophthalmopathy[J].J Clin Endocrinol Metab,1996,81:449-452.
• [21]Cawood TJ,Moriarty P,O'Farrelly C,et al.Smoking and thyroid-associated ophthalmopathy:A novel explanation of the biological link[J].J Clin Endocrinol Metab,2007,92:59-64.
• [22]Shan SJ,Douglas RS.The pathophysiology of thyroid eye disease[J].J Neuroophthalmol,2014,34:177-185.
• [23]Durrani OM,Reuser TQ,Murray PI.Infliximab:A novel treatment for sight-threatening thyroid associated ophthalmopathy[J].Orbit,2005,24:117-119.
• [24]Paridaens D,van den Bosch WA,van der Loos TL,et al.The effect of etanercept on Graves'ophthalmopathy:A pilot study[J].Eye,2005,19:1286-1289.
• [25]Ayabe R,Rootman DB,Hwang CJ,et al.Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease[J].Ophthal Plastic Reconstr Surg,2014,30:415-419.
• [26]van Steensel L,Paridaens D,van Meurs M,et al.Orbit-infil-trating mast cells,monocytes,and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in graves'ophthalmopathy[J].J Clin Endocrinol Metab,2012,97:E400-E408.
• [27]van Steensel L,Paridaens D,Schrijver B,et al.Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts:A potential treatment for Graves'ophthalmopathy[J].Invest Ophthalmol Vis Sci,2009,50:3091-3098.
• [28]Viraku S,Dalm VASH,Paridaens D,et al.The tyrosine kinase inhibitor dasatinib efficiently blocks PDGF-induced orbital fibroblast activation[J].Graefes Arch Clin Exp Ophthalmol,2014,252:1101-1109.
• [29]Kriss JV,Pleshakov V,Rosenblum AL,et al.Studies on the pathogenesis of the ophthahmopathy of Graves'disease[J].J Clin Endoerinol Metab,1967,27:582-593.
• [30]Kumar S,Coenen MJ,Scherer PE,et al.Evidence for enhanced adipogenesis in the orbits of patients with Graves'ophthalmopathy[J].J Clin Endocrinol Metab,2004,89:930-935.
• [31]Neumann S,Pope A,Geras-Raaka E,et al.A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of c AMP production in Graves'orbital fibroblasts[J].Thyroid,2012,22:839-843.
• [32]Turcu AF,Kumar S,Neumann S,et al.A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy[J].J Clin Endocrinol Metab,2013,98:2153-2159.
• [33]Chen H,Mester T,Raychaudhuri N,et al.Teprotumumab,an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes[J].J Clin Endocrinol Metab,2014,99:E1635-E1640.